Climb Bio (CLYM) Cash & Equivalents (2020 - 2026)
Climb Bio (CLYM) reported Cash & Equivalents of $44.11 million for Q2 2026, up 94.5% from $22.68 million a year earlier and up 427.8% from the prior quarter.
Powered by 
Analysis
Climb Bio (CLYM) Cash & Equivalents (2020 - 2026) Analysis & Trends
At the end of FY2025, Climb Bio posted Cash & Equivalents of $35.69 million, down 59.1% from FY2024.
- Cash & Equivalents has a five-year compound annual growth rate of 11.7% (FY2020 to FY2025).
- By year, Cash & Equivalents came in at $87.23 million in FY2024 (-6.3%), $93.11 million in FY2023 (+113.6%), $43.59 million in FY2022 (-7.1%) and $46.92 million in FY2021 (+129.0%).
- The Q2 2026 figure ranks as the highest quarterly Cash & Equivalents since Q4 2024.
- Year over year, Cash & Equivalents gained in two of the last eight quarters, with an average decline of 16.5%.
- The high point for year-over-year Cash & Equivalents in five years was Q2 2024 (growth of 782.2%); the low point was Q2 2025 (a decline of 89.8%).
- Per Business Quant data, the three quarters before Q2 2026 came in at $8.36 million (Q1 2026), $35.69 million (Q4 2025) and $25.8 million (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,082.65 Bn | 1,051.23 Bn | 19.71 Bn | 8.95 Bn |
| 2 | Johnson & Johnson | 623.68 Bn | 542.21 Bn | 17.26 Bn | 20.42 Bn |
| 3 | AbbVie | 459.43 Bn | 432.59 Bn | 12.70 Bn | 6.57 Bn |
| 4 | Merck | 354.80 Bn | 309.23 Bn | 12.21 Bn | 6.85 Bn |
| 5 | Novartis Ag | 269.16 Bn | 225.03 Bn | 11.24 Bn | 7.62 Bn |
| 6 | Astrazeneca | 244.40 Bn | 217.97 Bn | 12.86 Bn | 4.89 Bn |
| 7 | Amgen | 220.17 Bn | 175.57 Bn | 7.24 Bn | 13.99 Bn |
| 8 | Gilead Sciences | 183.05 Bn | 157.16 Bn | 6.22 Bn | 3.18 Bn |
| 9 | Pfizer | 160.27 Bn | 107.22 Bn | 10.94 Bn | 976.00 Mn |
| 10 | Climb Bio | 843.03 Mn | 843.03 Mn | - | 44.11 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 44.11 Mn |
| Mar 31, 2026 | 8.36 Mn |
| Dec 31, 2025 | 35.69 Mn |
| Sep 30, 2025 | 25.80 Mn |
| Jun 30, 2025 | 22.68 Mn |
| Mar 31, 2025 | 29.02 Mn |
| Dec 31, 2024 | 87.23 Mn |
| Sep 30, 2024 | 146.18 Mn |
| Jun 30, 2024 | 223.14 Mn |
| Mar 31, 2024 | 105.03 Mn |
| Dec 31, 2023 | 93.11 Mn |
| Sep 30, 2023 | 57.35 Mn |
| Jun 30, 2023 | 25.29 Mn |
| Mar 31, 2023 | 34.44 Mn |
| Dec 31, 2022 | 43.59 Mn |
| Sep 30, 2022 | 35.94 Mn |
| Jun 30, 2022 | 32.60 Mn |
| Mar 31, 2022 | 31.93 Mn |
| Dec 31, 2021 | 46.92 Mn |
| Sep 30, 2021 | 62.82 Mn |
API Access
Climb Bio Cash & Equivalents API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=cash-and-equivalents&ticker=CLYM&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "cash-and-equivalents", "ticker": "CLYM", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=cash-and-equivalents&ticker=CLYM&period=max&api_key=YOUR_API_KEY");
const data = await res.json();